The Medical Services Advisory Committee (MSAC) regularly seeks targeted feedback from Australian Genomics on genetic and genomic-related applications for public funding of medical services and technologies. Australian Genomics develops feedback for submissions by consulting with expert members drawn from its 450-strong network of professionals, to put forward unified, evidence-based submissions.
April 2021
Response to MSAC Application 1658: ‘Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS Olaparib’.
Response to MSAC Application 1660: ‘Diagnostic testing for mesenchymal-epithelial transition (MET) Exon 14 (METex14) skipping alterations in non-small cell lung cancer (NSCLC) to determine Pharmaceutical Benefits Scheme eligibility for tepotinib treatment’.
August 2021
Response to MSAC Application 1669 ‘KRAS G12C variant testing to determine eligibility for PBS subsidized sotorasib second-line therapy in patients with locally advanced or metastatic NSCLC’.
Response to MSAC Application 1671 ‘Carrier screening for severe monogenic disorders’.
November 2021
Response to MSAC Application 1675 ‘Whole Genome Sequencing for the diagnosis of mitochondrial disease’.
Response to MSAC Application 1680 ‘Genetic testing for childhood hearing impairment’.
Response to MSAC Application 1684 ‘Genetic testing for variants associated with haematological malignancies’.
October 2022
Response to MSAC Application 1721: ‘Small gene panel testing for non-small cell lung carcinoma.’